307547-35-9

Basic information

• Product Name: 2-[(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]-propanoic acid
• Synonyms: 2-[(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]-propanoic acid;2-(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yloxy)-propionic acid
• CAS NO: 307547-35-9
• Molecular Formula: C19H16O5
• Molecular Weight: 324.32734
• Mol File: 307547-35-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]-propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]-propanoic acid(307547-35-9)
• EPA Substance Registry System: 2-[(8-Methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]-propanoic acid(307547-35-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 307547-35-9(Hazardous Substances Data)

Usage

Explanation

This is the chemical name of the compound, which is derived from its structural formula.

Explanation

Warfarin is the widely recognized name for this chemical compound.

Explanation

Warfarin is classified as a medication that helps prevent blood clot formation.

Explanation

Warfarin works by inhibiting the activation of vitamin K, which is necessary for the production of blood-clotting factors.

Explanation

Warfarin is prescribed to prevent blood clot formation in specific medical conditions that increase the risk of clot formation.

Explanation

Warfarin can interact with various medications and foods, which may affect its efficacy or cause adverse effects.

Explanation

Warfarin has a narrow therapeutic window, meaning that the difference between a safe and effective dose is small, requiring careful monitoring and dosage adjustment.

Explanation

Patients taking warfarin often need to have their blood clotting levels monitored regularly to ensure the medication is working effectively and safely.

Chemical category

Anticoagulant medication

Mechanism of action

Inhibition of vitamin K activation

Medical uses

Prevention of blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism

Potential interactions

Interactions with other medications and foods

Therapeutic window

Narrow

Monitoring

Regular blood clotting level tests

Upstream product

• 21392-48-3 7-hydroxy-8-methyl-4-phenyl-chromen-2-one 
• 608-25-3 2-methylbenzene-1,3-diol 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 

Relevant articles and documents

Rational Design, Synthesis and Evaluation of Coumarin Derivatives as Protein-protein Interaction Inhibitors

Herein we describe the design and synthesis of a new series of coumarin derivatives searching for novel HIV-1 integrase (IN) allosteric inhibitors. All new obtained compounds were tested in order to evaluate their ability to inhibit the interaction between the HIV-1 IN enzyme and the nuclear protein lens epithelium growth factor LEDGF/p75. A combined approach of docking and molecular dynamic simulations has been applied to clarify the activity of the new compounds. Specifically, the binding free energies by using the method of molecular mechanics-generalized Born surface area (MM-GBSA) was calculated, whereas hydrogen bond occupancies were monitored throughout simulations methods.